Hbycsc Technology Co., Ltd
Inquire Now
Pharmaceutical Raw Materials >

Ixazomib Citrate Cas: 1201902-80-8 (Steroid E-Mail: Tom@Chembj.Com)

Detailed Selling Lead Description
Brand: YC
Model: Skype: tom131393
Price: USD 1 / g
Min. Order: 10 g g
Ixazomib Citrate CAS: 1201902-80-8

Product Name: Ixazomib Citrate
CAS: 1201902-80-8
MF: C20H23BCl2N2O9
MW: 517.12162
Product Categories: Apis;Inhibitor
density 1.47
Purity : 99%
Appearance : White powders
Package : 1kg/foil bag
Usage : MLN9708 is the first proteasome inhibitor to be administered in the early stages of multiple myeloma.

________________________________ For Your Reference ________________________________
Place of origin : China
Certificate : ISO9001:2008, KOSHER, GMP, SGS
Quality Standard : USP
Minimum Order Quantity : 10 g
Production Capacity : 1000 Kg/Month

________________________________ Package & Delivery ________________________________
Package : Foil bag, Foil tin , Drum or as your request
Payment Method : T/T, Western Union, MoneyGram, Bitcoin
Port of Loading : Shanghai, Shenzhen, Hongkong
Shipping Method : EMS, DHL, FeDex, UPS (Note: Best Choice For you will be adopted)
Leading time : Within 1 day upon confirming payment
Delivery time : Within 6 working days after confirming payment (Note: door to door service)

________________________________ Why Choose Us ? ________________________________
1. Professionalism: We specialized in exporting pharmaceutical intermediate for 15 years, you must want to find a professional manufacturer like us with much experience.
2. Quality : We are a professional leading factory for pharmaceutical intermediate in China, We had stable customers and exported to Germany, Spain, UK, USA, Australia, Middle East, and any other countries.
3. Package : Experienced package with special arrangement, high rate of customs clearance can be guaranteed.
4. Delivery: We have products in stock, so we will deliver them within 24 hours after payment. Tracking number will be given in no time.
5. Service : Best Service with after-sale service and consultation
Contact Us